MX2017009164A - Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos. - Google Patents

Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos.

Info

Publication number
MX2017009164A
MX2017009164A MX2017009164A MX2017009164A MX2017009164A MX 2017009164 A MX2017009164 A MX 2017009164A MX 2017009164 A MX2017009164 A MX 2017009164A MX 2017009164 A MX2017009164 A MX 2017009164A MX 2017009164 A MX2017009164 A MX 2017009164A
Authority
MX
Mexico
Prior art keywords
crac
channels
modulators
activated
release
Prior art date
Application number
MX2017009164A
Other languages
English (en)
Inventor
l greenberg Milton
T Ransom John
a white Clayton
S Muzaffery Omed
c newman Andrew
Original Assignee
Vivreon Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivreon Biosciences Llc filed Critical Vivreon Biosciences Llc
Publication of MX2017009164A publication Critical patent/MX2017009164A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en la presente compuestos que modulan la actividad de canales de CRAC, métodos para hacer tales compuestos, composiciones farmacéuticas y medicamentos que contienen tales compuestos y métodos para usar tales compuestos en el tratamiento de condiciones, enfermedades o trastornos asociados con actividad de canales de CRAC. (ver Dibujo).
MX2017009164A 2015-01-13 2016-01-11 Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos. MX2017009164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562103033P 2015-01-13 2015-01-13
PCT/US2016/012909 WO2016115054A2 (en) 2015-01-13 2016-01-11 Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
MX2017009164A true MX2017009164A (es) 2018-03-06

Family

ID=56406559

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009164A MX2017009164A (es) 2015-01-13 2016-01-11 Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos.

Country Status (10)

Country Link
US (1) US10213412B2 (es)
EP (1) EP3245189B1 (es)
JP (1) JP6764866B2 (es)
CN (1) CN107207431B (es)
AU (1) AU2016207014B2 (es)
CA (1) CA2969814C (es)
ES (1) ES2825798T3 (es)
HK (1) HK1245797A1 (es)
MX (1) MX2017009164A (es)
WO (1) WO2016115054A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016207014B2 (en) 2015-01-13 2020-07-16 Vivreon Biosciences, Llc Modulators of CA2+ release-activated CA2+ (CRAC) channels and pharmaceutical uses thereof
WO2019077496A1 (en) * 2017-10-17 2019-04-25 Rhizen Pharmaceuticals Sa CRAC CANAL MODULATORS FOR THE TREATMENT OF ESOPHAGE CANCER
KR20200079256A (ko) * 2017-10-30 2020-07-02 리젠 파마슈티컬스 소시에떼 아노님 혈액암 및 고형암을 치료하기 위한 칼슘 방출-활성화된 칼슘 채널 조절제
AU2019340601A1 (en) 2018-09-14 2021-05-13 Rhizen Pharmaceuticals A G Compositions comprising a CRAC inhibitor and a corticosteroid and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4644009A (en) 1984-10-29 1987-02-17 Usv Pharmaceutical Corporation Aryl-alkyl heterocyclic compounds
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
WO1993017671A1 (en) * 1992-03-06 1993-09-16 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites, or bacteria
ES2185693T3 (es) 1994-01-19 2003-05-01 Sankyo Co Derivado de pirrolopiridacina.
JP3143571B2 (ja) * 1994-01-19 2001-03-07 三共株式会社 ピロロピリダジン誘導体
JP2000256358A (ja) * 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
CA2580852A1 (en) * 2004-09-21 2006-03-30 Synta Pharmaceutical Corp. Compounds for inflammation and immune-related uses
KR20080024533A (ko) * 2005-06-24 2008-03-18 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
US8377970B2 (en) * 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
TW201130488A (en) * 2010-02-03 2011-09-16 Daiichi Sankyo Co Ltd Pyrrole compound
EA022973B1 (ru) * 2011-06-27 2016-03-31 Ньюрон Фармасьютикалс С.П.А. Фторированные арилалкиламинокарбоксамидные производные
WO2014203150A1 (en) * 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
AU2016207014B2 (en) 2015-01-13 2020-07-16 Vivreon Biosciences, Llc Modulators of CA2+ release-activated CA2+ (CRAC) channels and pharmaceutical uses thereof

Also Published As

Publication number Publication date
CN107207431B (zh) 2021-02-09
US10213412B2 (en) 2019-02-26
JP6764866B2 (ja) 2020-10-07
CN107207431A (zh) 2017-09-26
EP3245189A4 (en) 2018-07-18
AU2016207014B2 (en) 2020-07-16
AU2016207014A1 (en) 2017-07-06
EP3245189B1 (en) 2020-07-22
JP2018502083A (ja) 2018-01-25
HK1245797A1 (zh) 2018-08-31
ES2825798T3 (es) 2021-05-17
CA2969814C (en) 2023-06-13
WO2016115054A3 (en) 2016-09-01
CA2969814A1 (en) 2016-07-21
US20180263960A1 (en) 2018-09-20
WO2016115054A2 (en) 2016-07-21
EP3245189A2 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
CA2956871C (en) Compounds active towards bromodomains
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
MY188139A (en) Sodium channel modulators for the treatment of pain
GB2541571A (en) Pharmaceutical compositions
PH12019502646A1 (en) Pyrazole magl inhibitors
MY192588A (en) Pharmaceutical compounds
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
PH12017500494A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
PH12016500432B1 (en) Inhibitors of erk and methods of use
AU2018348359A8 (en) Extended release pharmaceutical formulation and methods of treatment
MX2020013085A (es) Antagonistas del receptor de subtipo 2 de melanocortina (mc2r) y usos de los mismos.
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
EP3328864A4 (en) COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
MX2017009164A (es) Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos.
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2021008941A (es) Moduladores gpr35.
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).